4 The overarching issue is that patients need more innovative, personalised therapies that target myeloma in different ways. We know that myeloma cells are highly heterogeneous. They multiply in ...
In our personalised medicine focus month, Katherine Bonter discusses the developments and challenges in personalised medicine relating to intellectual property and commercialisation. Value chains ...